GO
Loading...

Isis Pharmaceuticals Inc

More

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • Isis beats Street 4Q forecasts Friday, 27 Feb 2015 | 10:21 AM ET

    CARLSBAD, Calif. _ Isis Pharmaceuticals Inc. on Friday reported fourth-quarter net income of $31.1 million, after reporting a loss in the same period a year earlier. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 9 cents per share. Analysts expected $82.6 million, according to Zacks.

  • Lightning Round: It's part of a major revolution Thursday, 12 Feb 2015 | 7:19 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Why you should buy Box again Thursday, 5 Feb 2015 | 7:48 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Tuesday's midday movers: Target, Lear, NYT & more Tuesday, 3 Feb 2015 | 1:01 PM ET

    Take a look at some of Tuesday's midday movers:

  • Feb 3- Isis Pharmaceuticals Inc's experimental diabetes drug took a longer-than-expected 36 weeks to reduce blood sugar levels in patients with type 2 diabetes. Deutsche Bank's Alethia Young said the data looked less robust that some commonly prescribed treatments and Isis's own experimental glucagon receptor, ISIS-GCGR. Type 2 diabetes is a chronic...

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar in patients with type 2 diabetes. The drug, ISIS-PTP1B, was tested against a placebo in a mid-stage study comprising 92 type 2 diabetes patients with uncontrolled blood sugar, despite treatment. Type 2 diabetes is a chronic condition...

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar of patients with type 2 diabetes.

  • Lightning Round: What to do with McDonald's Wednesday, 28 Jan 2015 | 6:47 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Lightning Round: Wait on this rocket ship stock Tuesday, 13 Jan 2015 | 7:43 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: The MVPs of today’s market Tuesday, 13 Jan 2015 | 7:07 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the CEOs coaching their companies to new highs.

  • Cramer Remix: Buy into this weakness Tuesday, 6 Jan 2015 | 7:03 PM ET
    Jim Cramer on Mad Money.

    The recent selloffs have been ugly, but "Mad Money" host Jim Cramer thinks you can buy these stocks into the red arrows.

  • Cramer Remix: This is where the market goes in '15 Monday, 5 Jan 2015 | 7:01 PM ET
    Jim Cramer on Mad Money.

    We started off with an ugly trade Monday, but that does not stop "Mad Money" host Jim Cramer from making a bold prediction.

  • Midday movers: Exxon Mobil, Chevron, Hess & more Monday, 5 Jan 2015 | 12:56 PM ET

    Some of Monday's midday movers:

  • Jan 5- Johnson& Johnson will pay Isis Pharmaceuticals Inc up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel. Isis Pharmaceuticals said it will receive $35 million in an upfront payment and will be eligible to receive royalties on sales of the drugs. Janssen Biotech Inc, a unit of J&J, will have the right to license a...

  • Cramer Remix: The most exciting stock I've seen Thursday, 18 Dec 2014 | 6:55 PM ET
    Jim Cramer on Mad Money.

    Is this breakout story on your radar? "Mad Money" host Jim Cramer is about to put it there.

  • Cramer: Watch out Regeneron, here comes Isis Thursday, 18 Dec 2014 | 6:33 PM ET

    Jim Cramer is always looking for the next big biotech stock. He has found one that is a real game-changer, thanks to this new drug.

  • Cramer Remix: With oil going down, sell this asap Wednesday, 10 Dec 2014 | 7:01 PM ET

    It’s a popular yield play, but the tables have turned due to low oil prices."Mad Money" host Jim Cramer thinks it needs to be sold immediately.

  • Cramer Remix: The best stocks to own now Tuesday, 2 Dec 2014 | 7:07 PM ET

    It’s this stock, and its partner in crime, that "Mad Money" host Jim Cramer believes are heading higher.